Proactive Investors - Run By Investors For Investors

Amphion Innovations partner Kromek secures US$1.5m contract from UMASS

Amphion Innovations partner Kromek secures US$1.5m contract from UMASS

Amphion Innovations (LON:AMP) announced that its partner company Kromek has successfully secured a four year contract with the University of Massachusetts Medical School.

Kromek and UMASS will develop an advanced system for breast cancer detection and diagnosis, which it said could change the way this disease is detected.

The contract, which is worth US$1.5 million to Kromek, was funded via US$4 million from the US National Institute for Health (NIH).

X-ray mammography, which is considered the imaging mode of choice for early detection of breast cancer, records images that represent a three-dimensional (3D) object in a two-dimensional (2D) plane, meaning that normal breast tissue versus tumour tissue can be difficult to distinguish.

Kromek claims its technology can achieve better resolutions of breast tissue without increasing doses of radiation for patients, while the contract has potential to “significantly advance clinical diagnostics, in the field of breast cancer detection, and potentially way beyond”.

"Kromek and NOVA possess a unique technological answer to the challenge of achieving better resolutions of breast tissue, without increasing doses of radiation for patients," Amphion said in the statement.

“The modality we are using, which combines photon counting and cone-beam CT imaging, holds unique promise for the medical imaging market.

“We are looking forward to working together with Kromek and NOVA towards a solution that could change the way breast cancer detection is carried out for many years to come,” said professor of radiology at the University of Massachussets Stephen Glick.

Growth in the mammography market is influenced rising incidence of breast cancer in industrialised as well as developing nations.

The US mammography equipment market is forecast to be worth US$585 million per annum by 2015.

The deal will further expand Kromek’s presence in the medical imaging market, following the announcement earlier this month about our work with Siemens on CT imaging development in Germany and the US.

Just a month ago, Kromek secured official EU certification to provide colour x-ray liquid detection systems to all European airports.

This means that all airports on the continent are free to buy and implement Kromek’s Bottle Scanner product, marking the first time that airports can purchase tested, approved, and secure technology, allowing them to relax the liquid ban.

The technology is set to loosen up security restrictions for air passengers as it will eliminate the ban on carrying liquids on flights by April 2013.

Kromek is seen as the likeliest partner company of Ampion to be the next to become publicly traded.

According to Ampion chief executive Richard Morgan, the earliest the business can be floated would be during the first quarter of 2011, at which point Amphion’s 16% stake should be worth far more than the last valuation of £9 million.

For comparison, Amphion’s current market cap is around £6.4 million.

Meanwhile, Kromek itself managed to raise £12.3 million in an oversubscribed financing in March this year.

View full AMP profile View Profile

Amphion Innovations Plc Timeline

Related Articles

September 18 2017
Broker Numis thinks the benefits of the NetDimensions deal will be felt in the fourth quarter
Buying online
November 14 2017
The company toned down full-year revenue guidance after a review of procedures but is still growing like topsy
XTEK: Access latest PPT from Proactive's CEO Sessions
June 18 2017
Philippe Odouard talked growing revenues with investors.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use